Epiomic Epidemiology Series: Ovarian Cancer Forecast in 17 Major Markets 20152025 [Updated: 16092015] Prices from USD $6100

06:30 EDT 23 Jun 2017 | BioPortfolio Reports

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Ovarian Cancer in 17 Major Markets
Ovarian Cancer begins in the ovaries, resulting from abnormal cells that have the ability to spread to other parts of the reproductive system and, in advanced stages, other parts of the body. The cause for Ovarian Cancer is not currently known, most DNA mutations for ovarian cancer are acquired genetic changes, however a link still has not yet been found to any environmental factors that may cause the mutation. This report provides the current incidence population for Ovarian Cancer across 17 Major Markets USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Australia, Canada, Mexico, Turkey, South Africa, Saudi Arabia, Argentina and Russia split by gender and 5year age cohort. Along with the current incidence, the report provides an overview of the stages, grades and associated Charlson Comorbidity scoring of Ovarian Cancer. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a valueadded level of insight from the analysis team at Black Swan, several of the main symptoms and comorbidities of Ovarian Cancer have been quantified and presented alongside the overall prevalence figures. These subpopulations within the main disease are also included at a country level across the 10year forecast snapshot.
Main symptoms and comorbidities for Ovarian Cancer include:
Myocardial Infarct
Mild Liver Disease
Congestive Heart Failure
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
Able to quantify patient populations in global Ovarian Cancer's market to target the development of future products, pricing strategies and launch plans.
Gain further insight into the prevalence of the subdivided types of Ovarian Cancer and identify patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Provide a level of understanding on the impact from specific comorbid conditions on Ovarian Cancer's prevalent population.
Identify subpopulations within Ovarian Cancer which require treatment.
Gain an understanding of the specific markets that have the largest number of Ovarian Cancer patients.

Original Article: Epiomic Epidemiology Series: Ovarian Cancer Forecast in 17 Major Markets 20152025 [Updated: 16092015] Prices from USD $6100


More From BioPortfolio on "Epiomic Epidemiology Series: Ovarian Cancer Forecast in 17 Major Markets 20152025 [Updated: 16092015] Prices from USD $6100"

Quick Search


Relevant Topics

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...